IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
Moxifloxacin in the treatment of acute bacterial rhinosinusitis: Results of a multicenter, non-interventional study
Zhou, Bing1; Jiang, Xuejun2; Zhai, Lijie3; Xiao, Shuifang4; Wang, Jiadong5; Xiao, Gensheng6; Ruan, Biao7; Liang, Chuanyu8; Ye, Qing9; Hu, Baohua1; Wang, Haibo10
关键词Effectiveness Safety Tolerability
刊名ACTA OTO-LARYNGOLOGICA
2010-09-01
DOI10.3109/00016481003629036
130期:9页:1058-1064
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Otorhinolaryngology
研究领域[WOS]Otorhinolaryngology
英文摘要

Conclusion: Moxifloxacin was generally well tolerated and highly effective in the treatment of acute bacterial rhinosinusitis (ABS). The incidence of adverse events (AEs) and adverse drug reactions (ADRs) was low. The effectiveness, safety, and tolerability information collected in this study confirm the clinical safety profile of moxifloxacin and its benefit as a treatment option for ABS. Objective: To assess the effectiveness, safety, and tolerability of moxifloxacin under daily life treatment conditions in patients with ABS. Methods: The study was carried out in China between September 2005 and May 2007. Patients with ABS were treated with moxifloxacin tablets 400 mg once daily for a duration that was left to the physician′s discretion. Data were collected on demography, diagnosis of infection, pretreatment, concomitant diseases and medications, moxifloxacin therapy, course of symptoms during investigations, and final assessment of therapy. Results: In all, 578 patients with ABS treated with moxifloxacin were valid for effectiveness analysis. An improvement was observed in 98.8% (n = 571/578) of the patients. Cure was documented in 89.4% (n = 517/578) of the patients. The physicians′ overall tolerability rating was ′very good′ or ′good′ in 92.9% (n = 537/578) of patients. The incidence rates of AEs and ADRs were 1.5% (n = 10/681) and 0.6% (n = 4/681), respectively. No serious AE was reported.

语种英语
WOS记录号WOS:000282292600014
资助机构Bayer Healthcare Company Ltd
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/51158
专题北京大学第一临床医学院
作者单位1.China Med Univ, Hosp 1, ENT Dept, Beijing, Peoples R China
2.Peking Univ, Hosp 1, ENT Dept, Beijing, Peoples R China
3.Shanghai Renji Hosp, ENT Dept, Shanghai, Peoples R China
4.Capital Med Univ, Beijing Tongren Hosp, Dept Otolaryngol Head & Neck Surg, Key Lab Otolaryngol Head & Neck Surg,Minist Educ, Beijing 100730, Peoples R China
5.Dalian Med Univ, Affiliated Hosp 1, ENT Dept, Dalian, Peoples R China
6.Soochow Univ, Affiliated Hosp 1, ENT Dept, Suzhou, Peoples R China
7.Kunming Med Coll, Affiliated Hosp 1, ENT Dept, Kunming, Peoples R China
8.Sichuan Univ, W China Hosp, ENT Dept, Chengdu, Peoples R China
9.Fujian Prov Hosp, ENT Dept, Fuzhou, Peoples R China
10.Shandong Prov Hosp, ENT Dept, Jinan, Peoples R China
推荐引用方式
GB/T 7714
Zhou, Bing,Jiang, Xuejun,Zhai, Lijie,et al. Moxifloxacin in the treatment of acute bacterial rhinosinusitis: Results of a multicenter, non-interventional study[J]. ACTA OTO-LARYNGOLOGICA,2010,130(9):1058-1064.
APA Zhou, Bing.,Jiang, Xuejun.,Zhai, Lijie.,Xiao, Shuifang.,Wang, Jiadong.,...&Wang, Haibo.(2010).Moxifloxacin in the treatment of acute bacterial rhinosinusitis: Results of a multicenter, non-interventional study.ACTA OTO-LARYNGOLOGICA,130(9),1058-1064.
MLA Zhou, Bing,et al."Moxifloxacin in the treatment of acute bacterial rhinosinusitis: Results of a multicenter, non-interventional study".ACTA OTO-LARYNGOLOGICA 130.9(2010):1058-1064.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhou, Bing]的文章
[Jiang, Xuejun]的文章
[Zhai, Lijie]的文章
百度学术
百度学术中相似的文章
[Zhou, Bing]的文章
[Jiang, Xuejun]的文章
[Zhai, Lijie]的文章
必应学术
必应学术中相似的文章
[Zhou, Bing]的文章
[Jiang, Xuejun]的文章
[Zhai, Lijie]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。